“Accelerated approval recognizes that physicians and patients are generally willing to accept greater risks or side effects from products that treat life-threatening and severely-debilitating illnesses, than they would accept from products that treat less serious illnesses.”
Accelerated approval has been used in cancer trails, ALS trials, and in the case of Alzheimer’s when measurement of a drug’s effect is lengthy, expensive and there is an unmet need. Efficacy is proven later in a confirmatory trial.
If Blarcamesine is reasonably safe and if Anavex can show through a surrogate endpoint that Blarcamesine is “reasonably likely to predict clinical benefit”, it may gain accelerated approval. Efficacy may then be established later in a confirmatory trial. Approval of Aduhelm was unexpected. Scientist and doctors were saying it should not be approved because of efficacy and safety issues. Nevertheless, the FDA approved Aduhelm.
“In announcing its (Aduhelm’s) approval .., the F.D.A. acknowledged there was not sufficient evidence that the drug would help patients. Instead, it said it was greenlighting Aduhelm under a program called “accelerated approval,” which allows the authorization of drugs without persuasive proof of benefit if they are for serious diseases with few treatment options and if the drug affects part of the disease’s biology (known as a biomarker) in a way that is “reasonably likely to predict clinical benefit.””
Market Data 
Markets 
